Arbutus Biopharma (ABUS) Receivables - Net (2010 - 2026)
Arbutus Biopharma (ABUS) posted Receivables - Net of $178.7 million for Q1 2026, up 19650.39% sequentially from $905000.0 in Q3 2025, and up 15021.91% YoY from N/an in Q1 2025.
Arbutus Biopharma (ABUS) Receivables - Net (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Receivables - Net for 17 years, with the latest figure at $178.7 million in Q1 2026.
- Quarterly Receivables - Net rose 15021.91% year-over-year to $178.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.7 million (up 15021.91% YoY) and the FY2025 annual result came in at $1.4 million, down 39.93% from the prior year.
- Receivables - Net advanced to $178.7 million in Q1 2026 per ABUS's latest filing, from $905000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $178.7 million in Q1 2026 and troughed at $905000.0 in Q3 2025.
- A 5-year average of $12.8 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2025 and 2026: Receivables - Net slumped 44.74% in 2025, then surged 15021.91% in 2026.
- Over 5 years, Receivables - Net stood at $1.4 million in 2022, then surged by 31.36% to $1.8 million in 2023, then jumped by 35.64% to $2.4 million in 2024, then sank by 62.43% to $905000.0 in 2025, then surged by 19650.39% to $178.7 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $178.7 million, $905000.0, and $1.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 179.37 Mn |
| Jun 30, 2026 | 179.37 Mn |
| Mar 31, 2026 | 178.74 Mn |
| Mar 31, 2026 | 178.74 Mn |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 1.78 Mn |
| Dec 31, 2023 | 1.78 Mn |